Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models

In the fight against androgen-sensitive prostate cancer, the enzyme 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) is an attractive therapeutic target considering its key role in the formation of androgenic steroids. In this study, we attempted to assess the in vivo efficacy of the compound RM-5...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenmogne, Lucie Carolle, Roy, Jenny, Maltais, René, Rouleau, Mélanie, Neveu, Bertrand, Pouliot, Frédéric, Poirier, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300232/
https://www.ncbi.nlm.nih.gov/pubmed/28182747
http://dx.doi.org/10.1371/journal.pone.0171871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300232/
https://www.ncbi.nlm.nih.gov/pubmed/28182747
http://dx.doi.org/10.1371/journal.pone.0171871

Ejemplares similares